The new findings reveal how tumourous cancer cells are most active when the patient is resting, and have the tendency to jump into the blood to infect another organ in the body.
While prostate cancer is widespread in the west, urologists in India are seeing a major upsurge in the disease these days. It is a slow-growing malignancy that typically has no symptoms in the early stages.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Major players in the trastuzumab biosimilar market are Amgen Inc., Pfizer Inc, Samsung Bioepis, Merck & Co., Biocon Limited, Mylan Inc., BioXpress Therapeutics, Celltrion, Teva Pharmaceutical Industries Ltd. and EirGenix, Inc.
The global trastuzumab biosimilars market is expected to decline from $1.27 billion in 2019 to $1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $3.12 billion in 2023 at a CAGR of 35.50%.